Assessing Tempus AI (TEM) Valuation After New Immune Profile Score Breakthrough

Simply Wall St.

昨天

Tempus AI (TEM) has drawn fresh attention after releasing clinical validation data on its Immune Profile Score test, which the company reports more accurately predicts which cancer patients benefit ...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2607040225"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2607040225\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2607040225?lang=zh_CN&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","is_english":true,"pubTime":"2026-01-30 19:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2607040225","market":"us","top_or_hot":-1,"title":"Assessing Tempus AI (TEM) Valuation After New Immune Profile Score Breakthrough","media":"Simply Wall St.","content":"<div>\n<p>Tempus AI (TEM) has drawn fresh attention after releasing clinical validation data on its Immune Profile Score test, which the company reports more accurately predicts which cancer patients benefit ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/assessing-tempus-ai-tem-valuation-after-new-immune-profile-s\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Tempus AI (TEM) Valuation After New Immune Profile Score Breakthrough</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Tempus AI (TEM) Valuation After New Immune Profile Score Breakthrough\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-30 19:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/assessing-tempus-ai-tem-valuation-after-new-immune-profile-s><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tempus AI (TEM) has drawn fresh attention after releasing clinical validation data on its Immune Profile Score test, which the company reports more accurately predicts which cancer patients benefit ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/assessing-tempus-ai-tem-valuation-after-new-immune-profile-s\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEM","symbol_name":"Tempus AI","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/assessing-tempus-ai-tem-valuation-after-new-immune-profile-s","article_id":"2607040225","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tem/tempus-ai/news/assessing-tempus-ai-tem-valuation-after-new-immune-profile-s","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2607040225","pubTimestamp":1769773030,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Tempus AI (TEM) has drawn fresh attention after releasing clinical validation data on its Immune Profile Score test, which the company reports more accurately predicts which cancer patients benefit from immune checkpoint inhibitors than conventional biomarkers.\nSee our latest analysis for Tempus AI.\nThose IPS results arrive after a busy month for Tempus AI, with the launch of Paige Predict in digital pathology and fresh attention from high profile investors such as ARK and Nancy Pelosi. Even...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEM":"Tempus AI","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4121":"生命科学工具和服务","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4611":"AI医疗","BK4543":"AI","BK4551":"寇图资本持仓","BK4587":"ChatGPT概念","BK4613":"AI应用软件","BK7095":"多种金属与采矿","BK4588":"碎股","BK4528":"SaaS概念","BK4585":"ETF&股票定投概念","BK4023":"应用软件"},"translate_title":"在新的免疫概况评分突破后评估Tempus AI(TEM)估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEM":1.98},"content_text":"Tempus AI (TEM) has drawn fresh attention after releasing clinical validation data on its Immune Profile Score test, which the company reports more accurately predicts which cancer patients benefit from immune checkpoint inhibitors than conventional biomarkers. See our latest analysis for Tempus AI. Those IPS results arrive after a busy month for Tempus AI, with the launch of Paige Predict in digital pathology and fresh attention from high profile investors such as ARK and Nancy Pelosi. Even with these headlines, the share price is US$63.51 after a recent 7 day share price decline of 7% and a 90 day share price decline of 29%, while the 1 year total shareholder return of 11.05% points to momentum that has cooled in the short term but remains positive over a longer period. If this kind of AI driven healthcare story interests you, it could be a good moment to scan other healthcare stocks that might be setting up for their next catalyst. With Tempus AI trading at US$63.51, currently at a reported 66.53% intrinsic discount and 38.43% below one analyst target, is the recent weakness an opportunity for future growth, or is the market already pricing this in? AdvertisementMost Popular Narrative: 27.8% Undervalued Tempus AI's most followed narrative pegs fair value at about $87.92 per share versus the last close at $63.51, framing the current price as a discount that rests on specific growth and profitability assumptions.  The analysts have a consensus price target of $72.727 for Tempus AI based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $90.0 and the most bearish reporting a price target of just $60.0.  Read the complete narrative. Curious what justifies a fair value well above the current price? Revenue expansion, margin uplift and a premium future earnings multiple sit at the core of this narrative. The model leans on compound growth and a shift from losses to meaningful earnings. Want to see how those ingredients combine to reach that valuation target? Result: Fair Value of $87.92 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on key risks, including tougher competition in genomics and AI data, as well as potential delays or limits on reimbursement for newer assays. Find out about the key risks to this Tempus AI narrative. Another View: Price Tag Versus Fair Ratio Our DCF model points to a fair value of $184.27 per share, which is well above the current $63.51 price and supports the idea that Tempus AI is undervalued. That is a very different message compared with a rich P/S ratio near 10x, so which signal do you trust more? Look into how the SWS DCF model arrives at its fair value. TEM Discounted Cash Flow as at Jan 2026 Build Your Own Tempus AI Narrative If you see the inputs differently, or would rather test your own assumptions against the data, you can shape a custom thesis in a few minutes with Do it your way. A great starting point for your Tempus AI research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision. Ready for more investment ideas? If Tempus AI is on your radar, do not stop there. Use this momentum to look for other stocks that fit the kinds of opportunities you want to focus on next.  Spot potential value early by scanning these 3523 penny stocks with strong financials that pair lower share prices with financial profiles you can scrutinize in detail. Target next generation growth themes by filtering for these 24 AI penny stocks that are tied to artificial intelligence in practical, revenue producing ways. Seek mispriced opportunities by sorting through these 868 undervalued stocks based on cash flows that trade below estimates based on their cash flow profiles and business fundamentals.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Tempus AI might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}